|Iniparib (BSI-201)PARP1 inhibitor,intravenously adminsitered|
Sample solution is provided at 25 µL, 10mM.
Publications citing ApexBio Products
|Description||Iniparib (BSI-201) is an intravenously administered inhibitor of PARP1|
|Cas No.||160003-66-7||SDF||Download SDF|
|Solubility||Soluble in DMSO > 10 mM||Storage||Store at -20°C|
Iniparib, previously named BSI-201, is an intravenously administered PARP1 inhibitor, which either alone or in combination with chemotherapy, has important antitumor activity in studies in vitro and in vivo. It is active against a broad range of cancer cells in culture, including drug resistant cell lines. Iniparib has been reported to be a prodrug whose C-nitroso metabolite, 4-iodo-3-nitrosobenzamide, selectively kills tumor cells by oxidizing the zinc finger of PARP-1 resulting in ejection of zinc and inhibition of PARP activity.
Liang H, Tan AR. Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer. IDrugs. 2010 Sep;13(9):646-56.
Xuesong Liu, Yan Shi, David X. Maag, Joann P. Palma, Melanie J. Patterson, Paul A. Ellis, Bruce W. Surber, Damien B. Ready, Niru B. Soni, Uri S. Ladror, Allison J. Xu, Ramesh Iyer, John E. Harlan, Larry R. Solomon, Cherrie K. Donawho, Thomas D. Penning, Eric F. Johnson, Alexander R. Shoemaker. Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor. Clinical Cancer Research. January 15, 2012 18; 510.
S. Kopetz, M. M. Mita, I. Mok, K. K. Sankhala, J. Moseley, B. M. Sherman, C. R. Bradley and A. W. Tolcher. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors. Journal of Clinical Oncology. (Meeting Abstracts) May 2008 vol. 26 no. 15_suppl 3577